Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1O5M

Structure of FPT bound to the inhibitor SCH66336

Summary for 1O5M
Entry DOI10.2210/pdb1o5m/pdb
Related1QBQ
DescriptorProtein farnesyltransferase alpha subunit, Protein farnesyltransferase beta subunit, ZINC ION, ... (6 entities in total)
Functional Keywordsprotein inhibitor complex, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceRattus norvegicus (Norway rat)
More
Total number of polymer chains2
Total formula weight93894.93
Authors
Strickland, C.L.,Weber, P.C.,Ganguly, A.K. (deposition date: 2003-09-26, release date: 2003-10-21, Last modification date: 2023-12-27)
Primary citationStrickland, C.L.,Weber, P.C.,Windsor, W.T.,Wu, Z.,Le, H.V.,Albanese, M.M.,Alvarez, C.S.,Cesarz, D.,del Rosario, J.,Deskus, J.,Mallams, A.K.,Njoroge, F.G.,Piwinski, J.J.,Remiszewski, S.,Rossman, R.R.,Taveras, A.G.,Vibulbhan, B.,Doll, R.J.,Girijavallabhan, V.M.,Ganguly, A.K.
Tricyclic Farnesyl Protein Transferase Inhibitors: Crystallographic and Calorimetric Studies of Structure-Activity Relationships
J.Med.Chem., 42:2125-2135, 1999
Cited by
PubMed Abstract: Crystallographic and thermodynamic studies of farnesyl protein transferase (FPT) complexed with novel tricyclic inhibitors provide insights into the observed SAR for this unique class of nonpeptidic FPT inhibitors. The crystallographic structures reveal a binding pattern conserved across the mono-, di-, and trihalogen series. In the complexes, the tricycle spans the FPT active site cavity and interacts with both protein atoms and the isoprenoid portion of bound farnesyl diphosphate. An amide carbonyl, common to the tricyclic compounds described here, participates in a water-mediated hydrogen bond to the protein backbone. Ten high-resolution crystal structures of inhibitors complexed with FPT are reported. Included are crystallographic data for FPT complexed with SCH 66336, a compound currently undergoing clinical trials as an anticancer agent (SCH 66336, 4-[2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1, 2-b]pyridin-11-yl)-1-piperidinyl]-2-oxoethyl]-1-piperidinecarbo xamide ). Thermodynamic binding parameters show favorable enthalpies of complex formation and small net entropic contributions as observed for 4-[2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-11H-benzo[5, 6]cyclohepta[1, 2-b]pyridin-11-ylidene)-1-piperidinyl]-2-oxoethyl]pyridine N-oxide where DeltaH degrees bind = -12.5 kcal/mol and TDeltaS degrees bind = -1.5 kcal/mol.
PubMed: 10377218
DOI: 10.1021/jm990030g
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.3 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon